0000000000780804

AUTHOR

Valerio Leotta

showing 1 related works from this author

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A R…

2019

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we report real life results of KRd given to 130 RRMM patients from 12 Sicilian Centers. Results: Median age was 62 years

Oncologymedicine.medical_specialtySalvage therapylcsh:MedicineContext (language use)Article03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicinesalvage therapyKRd regimen; multiple myeloma; salvage therapyMultiple myelomaLenalidomideCumulative dosebusiness.industrylcsh:RGeneral Medicinemedicine.diseaseCarfilzomibKRd regimenClinical trialmultiple myelomaTolerabilitychemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drug
researchProduct